Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
- PMID: 20335294
- DOI: 10.1136/thx.2008.110825
Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
Abstract
Objective: Distant metastasis after surgical resection is the most frequent cause of death in patients with non-small cell lung cancer (NSCLC). This study aimed to investigate the patterns of distant metastasis and the prognostic factors of postrecurrence survival in patients with resected stage I NSCLC with distant metastases.
Methods: The clinicopathological characteristics of 166 patients with distant metastases after complete resection of stage I NSCLC at Taipei Veterans General Hospital between 1980 and 2000 were retrospectively reviewed. The patients were divided into two groups according to patterns of distant metastasis (single or multiple organ metastases). Predictors of postrecurrence survival were analysed.
Results: The patterns of distant metastasis included single organ metastasis in 106 (63.9%) and multiple organ metastases in 60 (36.1%) patients. The 1- and 2-year postrecurrence survival rates for those with single organ metastasis were 30.2% and 15.1%, respectively. The most common site of single organ metastasis was bone (32.1%), followed by the brain (29.2%). Multivariate analysis revealed that disease-free interval >16 months (HR 0.534; 95% CI 0.288 to 0.990; p=0.046) and treatment for distant metastasis (including re-operation, chemotherapy and/or radiotherapy) (HR 0.245; 95% CI 0.089 to 0.673; p=0.006) were significant predictors of better postrecurrence survival in resected stage I NSCLC with single organ metastasis.
Conclusions: A longer disease-free interval is a favourable prognostic predictor for postrecurrence survival in resected stage I NSCLC with single organ metastasis. Treatment for distant metastasis significantly prolongs postrecurrence survival.
Similar articles
-
Postrecurrence survival in patients with stage I non-small cell lung cancer.Eur J Cardiothorac Surg. 2008 Sep;34(3):499-504. doi: 10.1016/j.ejcts.2008.05.016. Epub 2008 Jun 25. Eur J Cardiothorac Surg. 2008. PMID: 18579404
-
Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.Thorax. 2009 Mar;64(3):192-6. doi: 10.1136/thx.2007.094912. Thorax. 2009. PMID: 19252018
-
[Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].Ai Zheng. 2006 Nov;25(11):1419-22. Ai Zheng. 2006. PMID: 17094913 Chinese.
-
The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system.Eur J Cardiothorac Surg. 2008 Aug;34(2):438-43; discussion 443. doi: 10.1016/j.ejcts.2008.03.070. Epub 2008 May 27. Eur J Cardiothorac Surg. 2008. PMID: 18502660 Review.
-
Muscle metastasis from non-small cell lung cancer: two cases and literature review.Acta Clin Belg. 2014 Aug;69(4):302-4. doi: 10.1179/2295333714Y.0000000035. Epub 2014 May 29. Acta Clin Belg. 2014. PMID: 24871253 Review.
Cited by
-
Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.Biomark Insights. 2017 Mar 30;12:1177271917699850. doi: 10.1177/1177271917699850. eCollection 2017. Biomark Insights. 2017. PMID: 28469400 Free PMC article.
-
Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation.Cancers (Basel). 2022 Aug 27;14(17):4150. doi: 10.3390/cancers14174150. Cancers (Basel). 2022. PMID: 36077686 Free PMC article.
-
Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.Thorac Cancer. 2018 Nov;9(11):1492-1499. doi: 10.1111/1759-7714.12863. Epub 2018 Sep 25. Thorac Cancer. 2018. PMID: 30253058 Free PMC article.
-
Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.Thorac Cancer. 2019 Apr;10(4):832-838. doi: 10.1111/1759-7714.13008. Epub 2019 Feb 28. Thorac Cancer. 2019. PMID: 30821130 Free PMC article.
-
Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma.Dis Markers. 2018 Mar 18;2018:8956072. doi: 10.1155/2018/8956072. eCollection 2018. Dis Markers. 2018. PMID: 29743960 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical